Literature DB >> 20464374

Development and use of FRAX in osteoporosis.

J A Kanis1, E V McCloskey, H Johansson, A Oden, O Ström, F Borgström.   

Abstract

This paper reviews briefly the development and clinical use of FRAX in the development of assessment guidelines for osteoporosis.Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Several treatments are available that have been shown to decrease the risk of fracture, but problems arise in identifying individuals at high fracture risk so that treatments can be effectively targeted. Case finding can be enhanced by the consideration of clinical risk factors that provide information on fracture risk over and above that provided by bone mineral density measurements. The FRAX tool integrates information on fracture risk from clinical risk factors with or without the use of BMD and can be used to improve the targeting of individuals at high fracture risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464374     DOI: 10.1007/s00198-010-1253-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  33 in total

Review 1.  Assessment of fracture risk.

Authors:  John A Kanis; Frederik Borgstrom; Chris De Laet; Helena Johansson; Olof Johnell; Bengt Jonsson; Anders Oden; Niklas Zethraeus; Bruce Pfleger; Nikolai Khaltaev
Journal:  Osteoporos Int       Date:  2004-12-23       Impact factor: 4.507

Review 2.  Body mass index as a predictor of fracture risk: a meta-analysis.

Authors:  C De Laet; J A Kanis; A Odén; H Johanson; O Johnell; P Delmas; J A Eisman; H Kroger; S Fujiwara; P Garnero; E V McCloskey; D Mellstrom; L J Melton; P J Meunier; H A P Pols; J Reeve; A Silman; A Tenenhouse
Journal:  Osteoporos Int       Date:  2005-06-01       Impact factor: 4.507

Review 3.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

Authors:  J A Kanis; M Stevenson; E V McCloskey; S Davis; M Lloyd-Jones
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

4.  FRAX assessment of osteoporotic fracture probability in Switzerland.

Authors:  K Lippuner; H Johansson; J A Kanis; R Rizzoli
Journal:  Osteoporos Int       Date:  2009-06-11       Impact factor: 4.507

5.  Alcohol intake as a risk factor for fracture.

Authors:  John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse
Journal:  Osteoporos Int       Date:  2004-09-29       Impact factor: 4.507

6.  International variations in hip fracture probabilities: implications for risk assessment.

Authors:  John A Kanis; Olof Johnell; Chris De Laet; Bengt Jonsson; Anders Oden; Alan K Ogelsby
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

7.  Smoking and fracture risk: a meta-analysis.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; C De Laet; J A Eisman; S Fujiwara; H Kroger; E V McCloskey; D Mellstrom; L J Melton; H Pols; J Reeve; A Silman; A Tenenhouse
Journal:  Osteoporos Int       Date:  2004-06-03       Impact factor: 4.507

Review 8.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

9.  A family history of fracture and fracture risk: a meta-analysis.

Authors:  J A Kanis; H Johansson; A Oden; O Johnell; C De Laet; J A Eisman; E V McCloskey; D Mellstrom; L J Melton; H A P Pols; J Reeve; A J Silman; A Tenenhouse
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

10.  Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX).

Authors:  S Fujiwara; T Nakamura; H Orimo; T Hosoi; I Gorai; A Oden; H Johansson; J A Kanis
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

View more
  118 in total

1.  The use of computed tomography attenuation to evaluate osteoporosis following acute fractures of the thoracic and lumbar vertebra.

Authors:  Osa Emohare; Amanda Cagan; Robert Morgan; Rick Davis; Martin Asis; Julie Switzer; David W Polly
Journal:  Geriatr Orthop Surg Rehabil       Date:  2014-06

2.  Duration of anti-resorptive therapy for osteoporosis.

Authors:  Robert A Adler
Journal:  Endocrine       Date:  2015-10-03       Impact factor: 3.633

Review 3.  Assessment of fracture risk.

Authors:  Sanford Baim; William D Leslie
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

4.  Evaluation of bone mineral density loss in morbidly obese women after gastric bypass: 3-year follow-up.

Authors:  Nuria Vilarrasa; Patricia San José; Isabel García; Carmen Gómez-Vaquero; Pilar Medina Miras; Amador G Ruiz de Gordejuela; Carles Masdevall; Jordi Pujol; Joan Soler; José Manuel Gómez
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

Review 5.  Incident fractures in HIV-infected individuals: a systematic review and meta-analysis.

Authors:  Stephanie Shiau; Emily C Broun; Stephen M Arpadi; Michael T Yin
Journal:  AIDS       Date:  2013-07-31       Impact factor: 4.177

6.  The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis.

Authors:  Ratanapha Phuan-Udom; Nittaya Lektrakul; Wanruchada Katchamart
Journal:  Clin Rheumatol       Date:  2018-07-23       Impact factor: 2.980

7.  Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures.

Authors:  Guowei Li; Lehana Thabane; Alexandra Papaioannou; Jonathan D Adachi
Journal:  Bone       Date:  2015-04-25       Impact factor: 4.398

8.  Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications.

Authors:  Perry J Pickhardt; B Dustin Pooler; Travis Lauder; Alejandro Muñoz del Rio; Richard J Bruce; Neil Binkley
Journal:  Ann Intern Med       Date:  2013-04-16       Impact factor: 25.391

9.  miRNAs in circulation: mirroring bone conditions?

Authors:  Jian Huang; Di Chen
Journal:  J Bone Miner Res       Date:  2014-08       Impact factor: 6.741

10.  Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.

Authors:  O Bruyère; M Fossi; B Zegels; L Leonori; M Hiligsmann; A Neuprez; J-Y Reginster
Journal:  Rheumatol Int       Date:  2012-07-28       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.